Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

U.S. Warns Against Abbott HIV Drug in Premature Babies

March 9, 2011

On Tuesday, the Food and Drug Administration advised against using Kaletra (lopinavir/ritonavir) oral solution in premature babies, which can cause severe or possibly fatal health problems, and in all babies younger than 14 days. There is no safe, established dose for babies younger than two weeks, whether premature or full-term, FDA said.

Advertisement

The Kaletra oral solution contains alcohol and propylene glycol, and the inability of premature babies to eliminate propylene glycol can lead to adverse events, including "serious heart, kidney or breathing problems," said the notice to health professionals. FDA has received reports of serious problems in premature babies receiving Kaletra.

"Because the consequences of using Kaletra oral solution in babies immediately after birth can be severe or possibly fatal, the label is being revised to include the new warning," stated the notice. "The use of Kaletra oral solution should be avoided in premature babies until 14 days after their due date, or in full-term babies younger than 14 days of age unless a health care professional believes that the benefit of using Kaletra oral solution to treat HIV infection immediately after birth outweighs the risks. In such cases, FDA strongly recommends monitoring for increases in serum osmolality, serum creatinine, and other signs of toxicity."

For additional information, visit www.fda.gov/Drugs/DrugSafety/ucm246002.htm.

Back to other news for March 2011

Adapted from:
Reuters
03.08.2011; Susan Heavey


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates
More on HIV Medications
More News on Kaletra (Lopinavir/Ritonavir)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement